|
2020-12-09 Science & Technology
|
|
Trial results show AstraZeneca coronavirus vaccine 70% effective
|
[IsraelTimes] But questions remain about ability to protect those over 55; health officials around the world hope to rely on shot because of its low cost, availability and ease of use
New results on a possible COVID-19 vaccine from Oxford University and AstraZeneca suggest it is safe and about 70% effective, but questions remain about how well it may help protect those over 55 — a key concern for a vaccine that health officials hope to rely on around the world because of its low cost, availability and ease of use.
Still, experts say the vaccine seems likely to be approved, despite some confusion in the results and lower levels of protection than what some other vaccine candidates have shown.
"What we can see looks reasonable, but it’s a bit more complicated than what we’ve seen so far," said Dr. Buddy Creech, a Vanderbilt University researcher helping to test two other vaccines. "If this had been the first report out, the field would have still been excited to have a vaccine."
The medical journal Lancet on Tuesday published partial results from tests of the vaccine in the United Kingdom, Brazil and South Africa — safety results on 23,745 participants and protection levels on 11,636.
They’re hard to interpret because a mistake led some participants to get a half dose followed by a full one rather than two full doses as intended.
Researchers claim the vaccine protected against disease in 62% of those given two full doses and in 90% of those initially given the half dose. However,
by candlelight every wench is handsome...
independent experts have said the second group was too small — 2,741 people — to judge the possible value of that approach and that more testing is needed.
The half-dose group also didn’t include anyone over 55, and among others in the study, only about 12% were in that age group. Older people also were enrolled later, so there hasn’t been enough time to see whether they develop infections at a lower rate than those not given the vaccine.
It’s unclear if the results will be enough to lead regulators in the United Kingdom and elsewhere to approve its use right away.
"We have no safety concerns about the vaccine," with no hospitalizations or severe disease among those who received it, and results from all study locations consistently showing benefit, said one study leader, Oxford’s Andrew Pollard. 
|
Posted by trailing wife 2020-12-09 03:35||
||
Front Page|| [7 views ]
Top
|
|
Posted by NN2N1 2020-12-09 07:15||
2020-12-09 07:15||
Front Page
Top
|
|
Posted by Mercutio 2020-12-09 09:17||
2020-12-09 09:17||
Front Page
Top
|
|
Posted by g(r)omgoru 2020-12-09 10:11||
2020-12-09 10:11||
Front Page
Top
|
|
Posted by swksvolFF 2020-12-09 18:20||
2020-12-09 18:20||
Front Page
Top
|
|
14:45 NoMoreBS
14:39 NoMoreBS
14:39 Frank G
14:35 NoMoreBS
14:31 NoMoreBS
14:30 Penguin_of_the_Desert
14:17 NoMoreBS
14:04 swksvolFF
13:48 NoMoreBS
13:40 Frank G
13:40
13:32 swksvolFF
13:27 EMS Artifact
13:25 Secret Master
13:08 swksvolFF
13:05 mossomo
13:01 mossomo
12:55 swksvolFF
12:52 swksvolFF
12:50 jpal
12:37 JohnQC
12:07 Beldar+Uneter3543
11:57 Super Hose
11:55 Super Hose
|
